Georgia Ramsay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Georgia Ramsay has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Jon Emery
Nanyang Technological University 5 Singapore
4 shared publications - Sibel Saya
Department of General Practice and Primary Care and Collaborative Centre for Cancer Genomic Medicine University of Melbourne Melbourne Victoria Australia
3 shared publications - Jamie Jl Liew
The University of Melbourne
2 shared publications - Jennifer McIntosh
Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne , Bouverie Street, Carlton, VIC 3053
2 shared publications - Matthew Thoenig
Department of General Practice and Primary Care, Melbourne Medical School, University of Melbourne, Melbourne, Australia
2 shared publications - Michelle King
Movember Melbourne Victoria Australia
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
The SCRIPT Trial: A Randomised Controlled Trial of a Polygenic Risk Score to Tailor Colorectal Cancer Screening in Australian General Practice
Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.
- 1 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe SCRIPT Trial: A Randomised Controlled Trial of a Polygenic Risk Score to Tailor Colorectal Cancer Screening in Australian General Practice
Background: Polygenic risk scores (PRS) can predict an individual’s risk of colorectal cancer (CRC) enabling tailoring of screening. The SCRIPT trial tested a complex intervention, including a PRS, in general practice to increase risk-appropriate CRC screening completion.Methods: This was a stratified, individually randomised controlled trial in eight general practices in Victoria, Australia. Patients aged 45-70 were consecutively approached for participation. For those over 50, those due CRC screening were eligible. The SCRIPT intervention comprised a CRC PRS, risk-tailored screening recommendations, and a risk report provided in a consultation and sent to participants’ GP. Control consultations included a discussion and brochure focused on lifestyle CRC risk factors.The primary outcome was the proportion completing risk-appropriate CRC screening by 12 months. In the SCRIPT arm, risk-appropriate screening was defined using PRS- and family history-derived CRC risk; in the control arm, it was defined using family history criteria. National screening guidelines, timing, type and results of previous screening were considered in both arms. Outcome assessors were blind to allocation (no other blinding was possible).Findings: Between 19/04/2021 and 23/08/2022, 276 participants (66% of those eligible) were randomised (138 control, 138 intervention). Three were withdrawn (one in each arm deemed ineligible, one control participant withdrew all data). Intention-to-treat analysis included 137 intervention and 136 control participants. In the SCRIPT arm, 62.8% (n=86) completed risk-appropriate CRC screening within 12 months, compared to 47.8% (n=65) of control participants – an increase of 14.9% (95% confidence interval: 3.5%-26.4%, p=0.012).Interpretation: This is the first trial to show that personalised genomic cancer risk information can be effectively incorporated into a primary care intervention to increase appropriate cancer screening completion. This is a key finding for effective implementation of risk-stratified population cancer screening – ensuring the correct screening is recommended, while optimising participation.
- 30 December 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (4) , 731-755
Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic review
Timely diagnosis and treatment are important in lymphoma care. This systematic review examined articles published up to April 2025 which reported intervals from symptom onset to treatment initiation and a subset examining associations with health-related outcomes. Of 11,606 articles screened, 67 were included (23 reported associations). Significant heterogeneity was noted, with 27 intervals reported across various lymphoma subtypes. Methodological issues included poor reporting of interval variability, small sample sizes, and arbitrary interval categorization. Commonly reported intervals included symptom onset to diagnosis (articles; median range), (27; 26-217 days), symptom onset to first presentation (23; 9-91 days), first presentation to diagnosis (17; 15-126 days), and diagnosis to treatment start (25; 1-42 days). Most association studies considered treatment interval and survival, finding inconsistencies. Only few examined the length of diagnostic or patient interval impacts on health outcomes. Future research should apply the Aarhus Checklist - a tool designed to enhance precision and transparency in early cancer diagnosis research to improve the consistency and quality of interval reporting. Further, non-linear interval-survival associations should be explored to capture paradoxical effects.
- 30 December 2025
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (4) , 731-755
Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic review
Timely diagnosis and treatment are important in lymphoma care. This systematic review examined articles published up to April 2025 which reported intervals from symptom onset to treatment initiation and a subset examining associations with health-related outcomes. Of 11,606 articles screened, 67 were included (23 reported associations). Significant heterogeneity was noted, with 27 intervals reported across various lymphoma subtypes. Methodological issues included poor reporting of interval variability, small sample sizes, and arbitrary interval categorization. Commonly reported intervals included symptom onset to diagnosis (articles; median range), (27; 26-217 days), symptom onset to first presentation (23; 9-91 days), first presentation to diagnosis (17; 15-126 days), and diagnosis to treatment start (25; 1-42 days). Most association studies considered treatment interval and survival, finding inconsistencies. Only few examined the length of diagnostic or patient interval impacts on health outcomes. Future research should apply the Aarhus Checklist - a tool designed to enhance precision and transparency in early cancer diagnosis research to improve the consistency and quality of interval reporting. Further, non-linear interval-survival associations should be explored to capture paradoxical effects.
- Open Access
- 7 August 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (765) , e329-e338
GP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk
Background: A polygenic risk score (PRS) enables personalisation of cancer risk and supporting risk stratification for melanoma, colorectal, breast, and prostate cancers. Including a PRS in a cancer risk assessment can facilitate risk-appropriate cancer screening by incorporating an individual’s age, sex, family history, and genomic test results. GPs are the likely healthcare professionals to order PRS tests and deliver results to patients within existing preventative health models. Aim: To elucidate GPs’ perspectives on the use of PRSs to tailor cancer screening in the Australian primary care context. Design & setting: A qualitative study undertaken in Victoria, Australia with GPs involved in a series of studies and clinical trials evaluating PRS. Method: Thirty GPs were interviewed; they were either PRS naive or had experience of using PRSs in a research context. Participants had a broad spectrum of clinical experience and knowledge of genomics, reflecting the spectrum of experience and knowledge of GPs in Victoria, Australia. Inductive and deductive thematic analysis was conducted and aligned to the Consolidated Framework for Implementation Research. Results: Common themes identified were: general practice is the appropriate setting for PRS-based approaches, personalised approaches to cancer risk can prompt discussions about positive lifestyle changes, and tailored risk reports are useful tools for the communication of complex health information. Barriers identified by GPs included: time constraints on the delivery of preventative health care, education requirements to upskill GPs in genomics, possible psychosocial harms to patients identified as being at increased risk, life-insurance implications, and added pressure on an already struggling health system. Conclusion: These findings provide insight into the requirements for the implementation of PRSs in primary care, from the perspective of GPs.
- 7 August 2025
- Published by Royal College of General Practitioners in British Journal of General Practice
- Vol. 76 (765) , e329-e338
Open AccessGP perspectives on genomics in primary care: a qualitative study on using polygenic risk scores to evaluate cancer risk
Background: A polygenic risk score (PRS) enables personalisation of cancer risk and supporting risk stratification for melanoma, colorectal, breast, and prostate cancers. Including a PRS in a cancer risk assessment can facilitate risk-appropriate cancer screening by incorporating an individual’s age, sex, family history, and genomic test results. GPs are the likely healthcare professionals to order PRS tests and deliver results to patients within existing preventative health models. Aim: To elucidate GPs’ perspectives on the use of PRSs to tailor cancer screening in the Australian primary care context. Design & setting: A qualitative study undertaken in Victoria, Australia with GPs involved in a series of studies and clinical trials evaluating PRS. Method: Thirty GPs were interviewed; they were either PRS naive or had experience of using PRSs in a research context. Participants had a broad spectrum of clinical experience and knowledge of genomics, reflecting the spectrum of experience and knowledge of GPs in Victoria, Australia. Inductive and deductive thematic analysis was conducted and aligned to the Consolidated Framework for Implementation Research. Results: Common themes identified were: general practice is the appropriate setting for PRS-based approaches, personalised approaches to cancer risk can prompt discussions about positive lifestyle changes, and tailored risk reports are useful tools for the communication of complex health information. Barriers identified by GPs included: time constraints on the delivery of preventative health care, education requirements to upskill GPs in genomics, possible psychosocial harms to patients identified as being at increased risk, life-insurance implications, and added pressure on an already struggling health system. Conclusion: These findings provide insight into the requirements for the implementation of PRSs in primary care, from the perspective of GPs.
- Open Access
- 19 May 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-18
The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.
- 19 May 2023
- Published by Springer Nature in Trials
- Vol. 24 (1) , 1-18
Open AccessThe PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care
Background: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. Methods: The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18–65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. Discussion: This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.